The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
Open accessAbstract
BACKGROUND: Prior studies with the use of a prospective-retrospective design including archival tumor samples have shown that gene-expression assays provide clinically useful prognostic information. However, a prospectively conducted study in a uniformly treated population provides the highest level of evidence supporting the clinical validity and usefulness of a biomarker. METHODS: We performed a prospective trial involving women with hormone-receptor-positive, human epidermal growth factor receptor type 2 (HER2)-negative, axillary node-negative breast cancer with tumors of 1.1 to 5.0 cm in the greatest dimension (or 0.6 to 1.0 cm in the greatest dimension and intermediate or high tumor grade) who met established guidelines for the consideration of adjuvant chemotherapy on the basis of clinicopathologic features. A reverse-transcriptase-polymerase-chain-reaction assay of 21 genes was performed on the paraffin-embedded tumor tissue, and the results were used to calculate a score indicating the risk of breast-cancer recurrence; patients were assigned to receive endocrine therapy without chemotherapy if they had a recurrence score of 0 to 10, indicating a very low risk of recurrence (on a scale of 0 to 100, with higher scores indicating a greater risk of recurrence). RESULTS: Of the 10,253 eligible women enrolled, 1626 women (15.9%) who had a recurrence score of 0 to 10 were assigned to receive endocrine therapy alone without chemotherapy. At 5 years, in this patient population, the rate of invasive disease-free survival was 93.8% (95% confidence interval [CI], 92.4 to 94.9), the rate of freedom from recurrence of breast cancer at a distant site was 99.3% (95% CI, 98.7 to 99.6), the rate of freedom from recurrence of breast cancer at a distant or local-regional site was 98.7% (95% CI, 97.9 to 99.2), and the rate of overall survival was 98.0% (95% CI, 97.1 to 98.6). CONCLUSIONS: Among patients with hormone-receptor-positive, HER2-negative, axillary node-negative breast cancer who met established guidelines for the recommendation of adjuvant chemotherapy on the basis of clinicopathologic features, those with tumors that had a favorable gene-expression profile had very low rates of recurrence at 5 years with endocrine therapy alone. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT00310180.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R., Ma, J., Zou, Z., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21208 · Cited by 11,499
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,277
Self-citationTrastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Self-citationHammond, M. E. H., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., Fitzgibbons, P. L., Francis, G., Goldstein, N. S., Hayes, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.6529 · Cited by 4,213
Self-citationWolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.9984 · Cited by 4,030
Self-citationEarly Breast Cancer Trialists' Collaborative Group (EBCTCG) (2011) · The Lancet · doi:10.1016/s0140-6736(11)60993-8 · Cited by 3,075
Global patterns of cancer incidence and mortality rates and trends
Jemal, A., Center, M. M., DeSantis, C., & Ward, E. M. (2010) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-0437 · Cited by 2,778
Paik, S., Tang, G., Shak, S., Kim, C., Baker, J., Kim, W., Cronin, M., Baehner, F. L., Watson, D., Bryant, J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7985 · Cited by 2,579
Self-citationHarris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., Somerfield, M. R., Hayes, D. F., & Bast, R. C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.2364 · Cited by 2,217
Self-citationEarly Breast Cancer Trialists' Collaborative Group (EBCTCG) (2012) · The Lancet · doi:10.1016/s0140-6736(11)61625-5 · Cited by 2,089
Davies, C., Pan, H., Godwin, J., Gray, R., Arriagada, R., Raina, V., Abraham, M., Alencar, V. H. M., Badran, A., Bonfill, X., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61963-1 · Cited by 2,044
Self-citationGoss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032312 · Cited by 1,795
Self-citationWolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P., et al. (2014) · Archives of Pathology and Laboratory Medicine · doi:10.5858/arpa.2013-0953-sa · Cited by 1,762
Self-citationAlbain, K. S., Barlow, W. E., Shak, S., Hortobagyi, G. N., Livingston, R. B., Yeh, I.-T., Ravdin, P., Bugarini, R., Baehner, F. L., Davidson, N. E., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70314-6 · Cited by 1,407
Self-citationUse of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
Simon, R. M., Paik, S., & Hayes, D. F. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp335 · Cited by 1,037
Self-citationHudis, C. A., Barlow, W. E., Costantino, J. P., Gray, R. J., Pritchard, K. I., Chapman, J.-A. W., Sparano, J. A., Hunsberger, S., Enos, R. A., Gelber, R. D., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.3523 · Cited by 864
Self-citationDevelopment of the 21-Gene Assay and Its Application in Clinical Practice and Clinical Trials
Sparano, J. A., & Paik, S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.1068 · Cited by 617
Self-citationTamoxifen and Chemotherapy for Lymph Node-Negative, Estrogen Receptor-Positive Breast Cancer
Fisher, B., Dignam, J., Emir, B., Bryant, J., DeCillis, A., Wolmark, N., Wickerham, D. L., Dimitrov, N. V., Abramson, N., Atkins, J. N., et al. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.22.1673 · Cited by 521
Self-citationSgroi, D. C., Sestak, I., Cuzick, J., Zhang, Y., Schnabel, C. A., Schroeder, B., Erlander, M. G., Dunbier, A., Sidhu, K., Lopez-Knowles, E., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70387-5 · Cited by 399
Goldstein, L. J., Gray, R., Badve, S., Childs, B. H., Yoshizawa, C., Rowley, S., Shak, S., Baehner, F. L., Ravdin, P. M., Davidson, N. E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4501 · Cited by 369
Self-citationEfficacy of Adjuvant Chemotherapy in High-Risk Node-Negative Breast Cancer
Mansour, E. G., Gray, R., Shatila, A. H., Osborne, C. K., Tormey, D. C., Gilchrist, K. W., Cooper, M. R., & Falkson, G. (1989) · New England Journal of Medicine · doi:10.1056/nejm198902233200803 · Cited by 352
Self-citationBueno-de-Mesquita, J. M., van Harten, W. H., Retel, V. P., van 't Veer, L. J., van Dam, F. S., Karsenberg, K., Douma, K. F., van Tinteren, H., Peterse, J. L., Wesseling, J., et al. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70346-7 · Cited by 274
A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study
Drukker, C. A., Bueno‐de‐Mesquita, J. M., Retèl, V. P., van Harten, W. H., van Tinteren, H., Wesseling, J., Roumen, R. M. H., Knauer, M., van 't Veer, L. J., Sonke, G. S., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28082 · Cited by 227
Sparano, J. A., Zhao, F., Martino, S., Ligibel, J. A., Perez, E. A., Saphner, T., Wolff, A. C., Sledge, G. W., Wood, W. C., & Davidson, N. E. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.9271 · Cited by 222
Self-citationTang, G., Shak, S., Paik, S., Anderson, S. J., Costantino, J. P., Geyer, C. E., Mamounas, E. P., Wickerham, D. L., & Wolmark, N. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1331-z · Cited by 188
Self-citationBiomarker validation and testing
Hayes, D. F. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2014.10.004 · Cited by 167
Self-citationValidation of New Cancer Biomarkers: A Position Statement from the European Group on Tumor Markers
Duffy, M. J., Sturgeon, C. M., Sölétormos, G., Barak, V., Molina, R., Hayes, D. F., Diamandis, E. P., & Bossuyt, P. M. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2015.239863 · Cited by 159
Self-citationEffects of Screening and Systemic Adjuvant Therapy on ER-Specific US Breast Cancer Mortality
Muñoz, D. F., Near, A. M., van Ravesteyn, N. T., Lee, S. J., Schechter, C. B., Alagöz, O., Berry, D. A., Burnside, E. S., Chang, Y.-J., Chisholm, G. B., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju289 · Cited by 146
The MINDACT trial: The first prospective clinical validation of a genomic tool
Cardoso, F., Piccart, M. J., Veer, L. V., et al. (2007) · Molecular Oncology · doi:10.1016/j.molonc.2007.10.004 · Cited by 145
Carlson, R. W., Hudis, C. A., & Pritchard, K. I. (2006) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2006.0082 · Cited by 142
Self-citationNCCN Task Force Report: Adjuvant Therapy for Breast Cancer
Carlson, R. W., Brown, E., Burstein, H. J., Gradishar, W. J., Hudis, C. A., Loprinzi, C. L., Mamounas, E. P., Perez, E. A., Pritchard, K. I., Ravdin, P. M., et al. (2006) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2006.2001 · Cited by 140
Self-citationMansour, E. G., Gray, R. J., Shatila, A. H., Tormey, D. C., Cooper, M. R., Osborne, C. K., & Falkson, G. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.11.3486 · Cited by 94
Self-citationAdjuvant therapy for breast cancer — results from the USA consensus conference
Abrams, J. S. (2001) · Breast Cancer · doi:10.1007/bf02967528 · Cited by 68
Wong, W. B., Ramsey, S. D., Barlow, W. E., Garrison, L. P., & Veenstra, D. L. (2012) · Contemporary Clinical Trials · doi:10.1016/j.cct.2012.08.006 · Cited by 53
Selecting Breast Cancer Patients for Chemotherapy: The Opening of the UK OPTIMA Trial
Bartlett, J. M. S., Canney, P. A., Campbell, A., Cameron, D., Donovan, J., Dunn, J., Earl, H. M., Francis, A., Hall, P. S., Harmer, V., et al. (2012) · Clinical Oncology · doi:10.1016/j.clon.2012.10.005 · Cited by 42
Clinical Application of Gene Expression Profiling in Breast Cancer
Sparano, J. A., Fazzari, M. J., & Kenny, P. A. (2010) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2010.03.008 · Cited by 23
Self-citation
Cited by
Breast Cancer Treatment: A Review
Waks, A. G., & Winer, E. P. (2019) · JAMA · doi:10.1001/jama.2018.19323 · Cited by 4,804
Harbeck, N., Penault-Llorca, F., Cortes, J., Gnant, M., Houssami, N., Poortmans, P., Ruddy, K., Tsang, J., & Cardoso, F. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0111-2 · Cited by 3,024
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. E., Dees, E. C., Goetz, M. P., Olson, J. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804710 · Cited by 2,397
Self-citationHarbeck, N., & Gnant, M. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31891-8 · Cited by 2,280
Łukasiewicz, S., Czeczelewski, M., Forma, A., Baj, J., Sitarz, R., & Stanisławek, A. (2021) · Cancers · doi:10.3390/cancers13174287 · Cited by 1,960
Metadata
- Authors
- Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. E., Dees, E. C., Perez, E. A., Olson, J. A., Zujewski, J., Lively, T., Badve, S. S., Saphner, T. J., Wagner, L. I., Whelan, T. J., Ellis, M. J., Paik, S., Wood, W. C., Ravdin, P., Keane, M. M., Gomez Moreno, H. L., Reddy, P. S., Goggins, T. F., Mayer, I. A., Brufsky, A. M., Toppmeyer, D. L., Kaklamani, V. G., Atkins, J. N., Berenberg, J. L., & Sledge, G. W.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-11-19
- Volume
- 373
- Issue
- 21
- Pages
- 2005-2014
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2190954851
- Cited by
- 1,388
- References
- 37
- FWCI
- 51.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.